The incretin hormone receptors (GIPR and GLP-1R) are widely distributed beyond the pancreas, principally in the brain, cardiovascular and immune systems, gut and kidney, consistent with a broad array of extrapancreatic incretin actions
Gentle, well-tolerated options may be better for GLP-1 users who already have stomach discomfort
For type 2 diabetes, treatment duration depends on ongoing glycaemic control and tolerability, often requiring long-term therapy
Code Description Notes G9919-TH Positive comprehensive risk screening and provision of recommendations/referrals (Screening only positive if there is a DX code associated with the non-clinical risk factor indicated) At least one non-clinical risk factor Z-code should be included when billing G9919-TH G9920-TH Negative comprehensive risk screening (No non-clinical risk factor DX code reported) No risk factor Z-codes should be submitted when billing G9920-TH Prenatal screenings require a Gestational Age DX code
For example, Lilly is studying orforglipron, a daily oral non-peptide GLP-1 agonist which is easier and less costly to manufacture vs
Signaling Mechanism for Modulation by GLP-1 and Exendin-4 of GABA Receptors on Rat Retinal Ganglion Cells
